AU1166101A - Pharmaceutical combination comprising separate dosage forms in a compliance package of an inhibitor of hmg coa reductase and fibric acid derivative - Google Patents

Pharmaceutical combination comprising separate dosage forms in a compliance package of an inhibitor of hmg coa reductase and fibric acid derivative

Info

Publication number
AU1166101A
AU1166101A AU11661/01A AU1166101A AU1166101A AU 1166101 A AU1166101 A AU 1166101A AU 11661/01 A AU11661/01 A AU 11661/01A AU 1166101 A AU1166101 A AU 1166101A AU 1166101 A AU1166101 A AU 1166101A
Authority
AU
Australia
Prior art keywords
inhibitor
dosage forms
acid derivative
coa reductase
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11661/01A
Inventor
Alexandros Alexidis
Demetrius Spyriounis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1166101A publication Critical patent/AU1166101A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU11661/01A 1999-11-09 2000-11-08 Pharmaceutical combination comprising separate dosage forms in a compliance package of an inhibitor of hmg coa reductase and fibric acid derivative Abandoned AU1166101A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR99100388 1999-11-09
GR990100388 1999-11-09
PCT/GR2000/000032 WO2001037831A1 (en) 1999-11-09 2000-11-08 PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND FIBRIC ACID DERIVATIVE

Publications (1)

Publication Number Publication Date
AU1166101A true AU1166101A (en) 2001-06-04

Family

ID=10943967

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11661/01A Abandoned AU1166101A (en) 1999-11-09 2000-11-08 Pharmaceutical combination comprising separate dosage forms in a compliance package of an inhibitor of hmg coa reductase and fibric acid derivative

Country Status (3)

Country Link
AU (1) AU1166101A (en)
GR (1) GR990100388A (en)
WO (1) WO2001037831A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030076715A (en) * 2001-03-01 2003-09-26 그레랑 파마수티컬 가부시키가이샤 Fenofibrate containing composition
EP1414496B1 (en) 2001-08-07 2010-10-20 Galephar M/F Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride
DE10200138A1 (en) * 2002-01-04 2003-07-17 Karl Winkler Composition, useful for the treatment of the atherogenic lipid phenotype found in e.g. type II diabetics, comprises agonist of peroxisome proliferator-activated receptor and inducer of low density lipoprotein receptor
ES2295816T3 (en) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. ARILO AND HETEROARILO 1,2,3-TRISUSTITUTED DERIVATIVES AS METABOLISM MODULATORS, AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THE SAME, SUCH AS DIABETES AND HYPERGLUCEMIA.
EP2287165A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005046662A2 (en) 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
KR20070038553A (en) 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 Novel statin pharmaceutical compositions and related methods of treatment
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
CN103539791B (en) 2010-09-22 2017-01-11 艾尼纳制药公司 Modulators of the GPR119 receptor and the treatment of disorders related thereto
MX2013006332A (en) * 2013-06-05 2014-12-19 Alparis Sa De Cv Oral pharmaceutical compositions for use in dyslipidemias.
CN107405332A (en) 2015-01-06 2017-11-28 艾尼纳制药公司 Treatment and S1P1The method of receptor related illness
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
EP3582772A1 (en) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis

Also Published As

Publication number Publication date
GR990100388A (en) 2001-07-31
WO2001037831A1 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
HK1200368A1 (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor hmg coa
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
HUP0301087A3 (en) Oral pharmaceutical composition comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
AU1166101A (en) Pharmaceutical combination comprising separate dosage forms in a compliance package of an inhibitor of hmg coa reductase and fibric acid derivative
IL154977A0 (en) Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
PT1306082E (en) PRESSURIZED CALIBRATED DOSE INHIBITORS AND AEROSOL PHARMACEUTICAL FORMULATIONS
IL150929A0 (en) Pharmaceutical compounds comprising a pharmaceutically active moiety and a moiety comprising a substituent that enhances its properties
DE69727299D1 (en) ANTITROMOMBOTIC ANTIATHEROSCLEROTIC PHARMACEUTICAL COMPOSITION OF A THIENOPYRIDINE DERIVATIVE AND AN HMG COA REDUCTASE INHIBITOR
GB9827391D0 (en) Aldose reductase inhibitors and pharmaceutical compositions
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
IS7061A (en) Dihydrogen N-substituted and a-substituted diphenylalkoxy acetic acid amino alkyl esters and drugs containing said compounds
HUP0303694A3 (en) Aza-amino acid derivatives and pharmaceutical
HUP0201615A2 (en) A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
AU5680900A (en) Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
AU2002240949A1 (en) Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
HUP0303497A3 (en) Pharmaceutical compositions containing combination of statins and sorbitol dehydrogenase inhibitors
AU6866700A (en) Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof
EP1225885A4 (en) A therapeutic mixture of hmg-coa reductase inhibitors
HUP0201597A3 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
PL337343A1 (en) Method of obtaining drugs comprising inhibitors of hmg coa reductase
AU2001289428A1 (en) Oral pharmaceutical composition containing a combination of fenofibrate and a hmg-coa reductase inhibitor
HUP0201016A3 (en) Pharmaceutical composition having synergistic effect containing amlodipine and atorvastatin metabolite
AU2002345121A1 (en) Products for use in immunosuppressive therapy containing lipoic acid and a calcineurin inhibitor
AU3387195A (en) Pharmaceutical compositions comprising a dihydrofolate reductase inhibitor and a dihydropteroate synthetase inhibitor
AU2002331468A1 (en) Oral pharmaceutical composition containing a combinaition of pparalpha and a hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase